More on NBIX
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $155.92 |
|
|||
| Open | $155.92 | ||||
| 52 Wk High | $58.46 | ||||
| 52 Wk Low | $31.25 | ||||
| Day High | $156.57 | ||||
| Day Low | $153.08 | ||||
| P/E | N/A | ||||
| EPS | $-0.69 | ||||
| Volume | 812,988 | ||||
- Neurocrine Bio. (NBIX) PT Lowered to $182 at Morgan Stanley
- Neurocrine's Ingrezza study shows quality-of-life gains in TD patients
- Neurocrine Biosciences Announces Publication of KINECT-PRO™ Findings Demonstrating INGREZZA® (valbenazine) Capsules Improved Patient-Reported Quality of Life and Daily Functioning for People Living
- Neurocrine starts Phase 1 trial of obesity drug NBIP-1968
- Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBIP-'1968, a GLP-1/GIP/Glucagon Receptor Triple Agonist
- Form 4 NEUROCRINE BIOSCIENCES For: Aug 04 Filed by: Onyia Jude
- Neurocrine Bio. (NBIX) PT Raised to $213 at Truist Securities
- H.C. Wainwright Reiterates Buy Rating on Neurocrine Bio. (NBIX)
- Neurocrine Bio. (NBIX) PT Raised to $210 at Canaccord
- Form S-8 NEUROCRINE BIOSCIENCES
Entities mentioned with NBIX
- FDA | View Related Stories »
- Earnings | View Related Stories »
- Twitter | View Related Stories »
- ARK | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- Definitive Agreement | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
